Terms of Use

Welcome to a website of Prasco, LLC d/b/a Prasco Laboratories (“Prasco”). By using the site, you agree to be bound by the following terms and all applicable laws and regulations. If you do not agree to these Terms of Use, you are not permitted to use the site. The information provided on this website is presented in summary form, is general in nature, and is provided for informational purposes only. The information on this site is intended only for informational purposes. The content is not intended in any way to be a substitute for professional medical advice and should not be interpreted as treatment recommendations. Only a physician who has had an opportunity to interact with the patient in person, with access to the patient’s records and the opportunity to conduct appropriate follow-up, can provide recommendations for treatment.

Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Neither the content nor any other service offered by or through this website is intended to be relied on for medical diagnosis or treatment, without a physician’s interaction and involvement. Never disregard medical advice or delay in seeking it because of something you have read on this website.

THIS SITE AND THE CONTENT ARE PROVIDED “AS IS”. PRASCO, ITS LICENSORS, AND ITS SUPPLIERS, TO THE FULLEST EXTENT PERMITTED BY LAW, DISCLAIM ALL WARRANTIES, EITHER EXPRESS OR IMPLIED, STATUTORY OR OTHERWISE, INCLUDING BUT NOT LIMITED TO THE IMPLIED WARRANTIES OF MERCHANTABILITY, NON-INFRINGEMENT OF THIRD PARTIES’ RIGHTS, AND FITNESS FOR PARTICULAR PURPOSE. SPECIFICALLY, PRASCO, ITS LICENSORS, AND ITS SUPPLIERS MAKE NO REPRESENTATIONS OR WARRANTIES ABOUT THE ACCURACY, RELIABILITY, COMPLETENESS, CURRENTNESS, SUITABILITY OR TIMELINESS OF THE CONTENT, SOFTWARE, TEXT, GRAPHICS, TOOLS, LINKS, OR COMMUNICATIONS PROVIDED ON OR THROUGH THE USE OF THE WEBSITE OR PRASCO, OR ON ANY SITE OR SITES “LINKED” TO THIS SITE. PRASCO MAKES NO WARRANTY THAT THE SITE WILL BE AVAILABLE, UNINTERRUPTED, ERROR FREE, OR FREE OF VIRUSES OR OTHER HARMFUL COMPONENTS.

TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, IN NO EVENT SHALL PRASCO, ITS LICENSORS, ITS SUPPLIERS, OR ANY THIRD PARTIES MENTIONED ON THE WEBSITE BE LIABLE FOR ANY DAMAGES (INCLUDING, WITHOUT LIMITATION, INCIDENTAL AND CONSEQUENTIAL DAMAGES, PERSONAL INJURY/WRONGFUL DEATH, LOST PROFITS, OR DAMAGES RESULTING FROM LOST DATA OR BUSINESS INTERRUPTION) RESULTING FROM THE USE OR INABILITY TO USE THE WEBSITE OR THE CONTENT OR ANY FAILURE OF PERFORMANCE, ERROR, OMISSION, INTERRUPTION, EFFECT, DELAY IN OPERATION OR TRANSMISSION, COMPUTER VIRUS, LINE SYSTEM FAILURE, LOSS OF DATA, OR LOSS OF USE RELATED TO THE SITE OR ANY WEB SITE OPERATED BY ANY THIRD PARTY, WHETHER BASED ON WARRANTY, CONTRACT, TORT, OR ANY OTHER LEGAL THEORY, AND WHETHER OR NOT PRASCO IS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES. IF YOU ARE DISSATISFIED WITH US, ANY OF OUR SERVICES OR THESE TERMS OF USE, YOUR SOLE AND EXCLUSIVE REMEDY IS TO DISCONTINUE USE OF THE SITE.

Any claims arising in connection with your use of the site or any content must be brought within one (1) year of the date of the event giving rise to such action occurred.

As a resource to our visitors, this site may provide links to other web sites. However, because we do not control the content of the other websites we may link to, and due to their constantly changing nature, we cannot be responsible for the content, practices or standards of third-party sites. Prasco does not endorse the content on any third-party websites. Prasco is not responsible for the content of linked third-party sites, sites framed within the site, or third-party advertisements, and does not make any representations regarding their content or accuracy. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.

Everything that you read or see on the site is copyrighted or otherwise protected and owned by Prasco or a third party who licensed or granted to Prasco the right to use such material. Unless otherwise expressly noted, nothing that you read or see on the site may be copied or used except as provided in these Terms of Use or with the prior written approval of Prasco.

We grant you permission to print individual pages from the site, unless otherwise expressly noted, for your own personal, non-commercial use in learning about the services or products offered by Prasco or for your non-commercial use in connection with health care or education. If you are a health care professional or provider, you may print individual pages from the site, unless otherwise expressly noted, and share the information and materials with others. No other permission is granted to you to print, copy, reproduce, distribute, license, transfer, sale, transmit, upload, download, store, display in public, alter, modify or create derivative works of these materials. This grant of permission is not a transfer of title, and under this permission you may not:

use the materials for any commercial purpose, or for any public display (commercial or non-commercial);

remove any copyright, trademark or other proprietary notations from the materials; or

transfer the materials to another person or “mirror” the materials on any other server.

We make no warranties or representations to you that your use of any materials displayed on the site will not infringe the rights of third parties.

Unless otherwise indicated, all logos, names, designs, and marks on the site are trademarks or service marks owned or used under license by Prasco. The use or misuse of any of these marks or other information is strictly prohibited. Nothing contained herein shall be construed as conferring by implication, estoppel or otherwise any license or right under any patent or trademark of Prasco or any third party.

Except as expressly provided above nothing contained herein shall be construed as conferring any license or right under any Prasco copyright. Except as expressly set forth on the site, if you submit any information to us, including any comments, remarks, suggestions, ideas, notes, drawings, graphics, concepts, or other information, you are giving that information, and all your rights in it, to Prasco free of charge and such information shall be deemed to be non-confidential and Prasco shall have no obligation of any kind with respect to such information and shall be free to reproduce, use, disclose and distribute the information to others without limitation, without your consent or any compensation to you or anyone else. Prasco shall be free to use any know-how or techniques contained in such information for any purpose whatsoever including but not limited to developing, manufacturing and marketing products incorporating such information. This is true whether you submit such information to us by e-mail, through a form on the site, on a bulletin board, or in any other manner. Prasco may from time to time monitor, review and, in its sole discretion, modify or delete any postings you make on the site however, Prasco is not obligated to do so.

You agree not to submit or transmit any material that is unlawful, threatening, libelous, defamatory, obscene, pornographic, profane, or might in any other way violate any law, regulation, or rule. You are solely responsible for any material you submit to the site. You further agree not to upload, email, post or transmit to, or distribute or otherwise publish through the site any material which disrupts the normal operation of the site, including posting or otherwise transmitting material that is not related to the subject at issue or otherwise restricts or inhibits any other user from using the site. Through your usage of the site, you may submit and/or Prasco may gather certain limited information about you and your website usage. We are free to use such information for any purpose we deem appropriate, including marketing purposes.

To obtain full access to the site, you may be required to complete a registration. You are responsible for maintaining the confidentiality of your account and password and for restricting access to your computer. You accept responsibility for all activities that occur under your account or password and such use shall be deemed to be use by you. You will ensure that all use of your account fully complies with these Terms of Use. Transfer of the account by you to any other person or entity is prohibited.

When using the site, information will be transmitted over a medium that is beyond the control and jurisdiction of Prasco and its suppliers. Accordingly, Prasco assumes no liability for or relating to the delay, failure, interruption, or corruption of any data or other information transmitted in connection with use of this site.

Prasco is located in Mason, Ohio, in the United States of America (USA). This site is intended for the exclusive use of residents of the USA. Prasco makes no representation that the materials on the site are appropriate or available for use in other locations. Access to the content may not be legal by certain persons or in certain countries outside of the USA. If you access this site from outside the United States, you do so at your own risk and are responsible for compliance with the laws of your jurisdiction.

These Terms and our Privacy Policy shall be governed in all respects by the laws of the State of Ohio without giving effect to its conflicts of law provisions. Both parties submit to the personal jurisdiction of and venue in the state and federal courts in the State of Ohio, within the judicial district that includes Warren, Butler, Hamilton and Clermont counties, Ohio for any disputes arising out of these Terms or our Privacy Policy. To the extent that the arbitration provision below is found not to apply, the parties agree that any cause of action arising under these Terms shall exclusively be brought in such courts. If any provision of these Terms or our Privacy Policy is held to be invalid or unenforceable, such provision shall be struck and the remaining provisions shall be enforced.

By using this website, you and Prasco agree that, if there is any controversy, claim, action, or dispute arising out of or related to your use of the website, or the breach, enforcement, interpretation, or validity of these Terms or any part of it (“Dispute”), both parties shall first try in good faith to settle such Dispute by providing written notice to the other party describing the facts and circumstances of the Dispute and allowing the receiving party thirty (30) days in which to respond or settle the Dispute. Notice shall be sent to:

Us, at Prasco, LLC, 6125 Commerce Court, Mason, OH 45040, Attn: Legal Department, or

You, at the address we have on file for you.

Both you and Prasco agree that this dispute resolution procedure is a condition precedent that must be satisfied before initiating any litigation or filing any claim against the other party. IF ANY DISPUTE CANNOT BE RESOLVED BY THE ABOVE DISPUTE RESOLUTION PROCEDURE, YOU AGREE THAT THE SOLE AND EXCLUSIVE JURISDICTION FOR SUCH DISPUTE WILL BE DECIDED BY BINDING ARBITRATION ON AN INDIVIDUAL BASIS. ARBITRATION ON AN INDIVIDUAL BASIS MEANS THAT YOU WILL NOT HAVE, AND YOU WAIVE, THE RIGHT FOR A JUDGE OR JURY TO DECIDE YOUR CLAIMS, AND THAT YOU MAY NOT PROCEED IN A CLASS, CONSOLIDATED, OR REPRESENTATIVE CAPACITY. Other rights that you and we would otherwise have in court will not be available or will be more limited in arbitration, including discovery and appeal rights. All such disputes shall be exclusively submitted to JAMS (www.jamsadr.com) for binding arbitration under its rules then in effect, before one arbitrator to be mutually agreed upon by both parties.

The arbitrator, and not any federal, state, or local court or agency, shall have exclusive authority to resolve any dispute arising under or relating to the interpretation, applicability, enforceability, or formation of these Terms, including any claim that all or any part of these Terms is void or voidable.

We may offer services or features that are subject to additional or different terms and conditions. We will notify you if the feature you are accessing is subject to terms and conditions that differ from these Terms, and you will have the opportunity to decline to participate in such sites or services, if you do not agree with the differing terms and conditions.

Prasco may modify these Terms of Use from at any time without notice to you. You should review these Terms of Use every time you access the website. Your continued use of this site constitutes acceptance of the Terms of Use then in effect.

Prasco may terminate this agreement, terminate your access to all or part of the site, or suspend any user’s access to all or part of the site, at any time, without notice to you, if it believes, in its sole judgment, that you have breached or may breach any term or condition of this agreement, or for its convenience. You may terminate this agreement at any time by destroying all materials received from the site and ceasing to use the site.

Prasco’s failure to act with respect to a breach by you or others does not waive its right to act with respect to subsequent or similar breaches.
These Terms shall not be assignable by you, either in whole or in part. Prasco reserves the right to assign its rights and obligations under these Terms.

These Terms and our Privacy Policy set forth the entire understanding and agreement between Prasco and you with respect to the subject matter hereof and supersede any prior or contemporaneous understanding, whether written or oral.

Questions about these Terms of Use should be directed to: legal@prasco.com.
Please use this email only for legal and privacy policy matters. For all other inquiries, refer to the Contact Us section of our home page.

These Terms of Use were last updated January 2020.

Unless otherwise indicated, all material on this site © 2020 Prasco. Other company and product names are trademarks of their respective owners.

All rights reserved.

PP-MA-PR-US-0045

Read More Collapse

INDICATIONS AND USAGE

ProCentra® (dextroamphetamine sulfate) is indicated in:

Narcolepsy

Attention Deficit Disorder with Hyperactivity: As an integral part of a total treatment program that typically includes other remedial measures (psychological, educational, social) for a stabilizing effect in pediatric patients (ages 3 to 16 years) with a behavioral syndrome characterized by the following group of developmentally inappropriate symptoms: Moderate to severe distractibility, short attention span, hyperactivity, emotional lability, and impulsivity. The diagnosis of this syndrome should not be made with finality when these symptoms are only of comparatively recent origin. Nonlocalizing (soft) neurological signs, learning disability, and abnormal EEG may or may not be present, and a diagnosis of central nervous system dysfunction may or may not be warranted.

IMPORTANT SAFETY INFORMATION

WARNING: ABUSE, MISUSE, AND ADDICTION

Dextroamphetamine sulfate has a high potential for abuse and misuse, which can lead to the development of a substance use disorder, including addiction. Misuse and abuse of CNS stimulants, including dextroamphetamine sulfate, can result in overdose and death. This risk is increased with higher doses or unapproved methods of administration, such as snorting or injection.

Before prescribing dextroamphetamine sulfate, assess each patient’s risk for abuse, misuse, and addiction. Educate patients and their families about these risks, proper storage of the drug, and proper disposal of any unused drug. Throughout dextroamphetamine sulfate treatment, reassess each patient’s risk of, and frequently monitor for signs and symptoms of, abuse, misuse, and addiction.

CONTRAINDICATIONS

  • Known hypersensitivity to amphetamine products.
  • During or within 14 days following the administration of monoamine oxidase inhibitors (hypertensive crisis may result).

WARNINGS AND PRECAUTIONS

  • Abuse, Misuse, and Addiction: See boxed warning above.
  • Risks to Patients with Serious Cardiac Disease: Sudden death has been reported in patients with structural cardiac abnormalities or other serious cardiac disease who are treated with CNS stimulants at the recommended ADHD dosages. Avoid ProCentra use in patients with known structural cardiac abnormalities, cardiomyopathy, serious cardiac arrhythmia, coronary artery disease, or other serious cardiac disease. Instruct patients to contact a healthcare provider immediately if they develop symptoms such as exertional chest pain, unexplained syncope, or other symptoms suggestive of cardiac disease.
  • Increased Blood Pressure and Heart Rate: CNS stimulants cause an increase in blood pressure (mean increase about 2 to 4 mm Hg) and heart rate (mean increase about 3 to 6 bpm). Monitor all patients for potential tachycardia and hypertension.
  • Psychiatric Adverse Reactions: Exacerbation of Pre-Existing Psychosis: CNS stimulants may exacerbate symptoms of behavior disturbance and thought disorder in patients with a pre-existing psychotic disorder. Induction of a Manic Episode in Patients with Bipolar Disorder: CNS stimulants may induce a manic or mixed episode in patients. Prior to initiating treatment, screen patients for risk factors for developing a manic episode (e.g., comorbid or history of depressive symptoms or a family history of suicide, bipolar disorder, or depression). New Psychotic or Manic Symptoms: CNS stimulants, at recommended doses, may cause psychotic or manic symptoms (e.g., hallucinations, delusional thinking, or mania) in patients without a prior history of psychotic illness or mania. If such symptoms occur, consider discontinuing dextroamphetamine sulfate.
  • Long-Term Suppression of Growth in Pediatric Patients: CNS stimulants have been associated with weight loss and slowing of growth rate in pediatric patients, including dextroamphetamine sulfate. Closely monitor growth (weight and height) in ProCentra-treated pediatric patients treated with CNS stimulants. Pediatric patients who are not growing or gaining height or weight as expected may need to have their treatment interrupted.
  • Seizures: There is some clinical evidence that stimulants may lower the convulsive threshold in patients with prior history of seizures, or prior EEG abnormalities in absence of seizures, and, very rarely, in patients without a history of seizures and no prior EEG evidence of seizures. In the presence of seizures, the drug should be discontinued.
  • Peripheral Vasculopathy, Including Raynaud’s Phenomenon: Stimulants, including dextroamphetamine sulfate oral solution, used to treat ADHD are associated with peripheral vasculopathy, including Raynaud’s phenomenon. Signs and symptoms are usually intermittent and mild; however, very rare sequelae include digital ulcerations and/or soft tissue breakdown. Signs and symptoms generally improved after dosage reduction or discontinuation of the CNS stimulant. Careful observation for digital changes is necessary during ProCentra-treatment. Patients should call their physician immediately with any signs of unexplained wounds appearing on fingers or toes while taking ProCentra. Further evaluation may be required, including rheumatology referral.
  • Serotonin Syndrome: Serotonin syndrome, a potentially life-threatening reaction, may occur when amphetamines are used with other drugs that affect the serotonergic neurotransmitter systems such as monoamine oxidase inhibitors (MAOI), selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, St. John’s Wort and cytochrome P450 (CYP2D6) inhibitors. Concomitant use of ProCentra with MAOI drugs is contraindicated. Discontinue treatment with ProCentra and any concomitant serotonergic agents immediately if serotonin syndrome symptoms occur (e.g., mental status changes, autonomic instability, neuromuscular symptoms, seizures, and/or gastrointestinal symptoms), and initiate supportive symptomatic treatment. If concomitant use of ProCentra with other serotonergic drugs or CYP2D6 inhibitors is clinically warranted, initiate ProCentra with lower doses, monitor patients for the emergence of serotonin syndrome during drug initiation or titration, and inform patients of the increased risk for serotonin syndrome.
  • Motor and Verbal Tics, and Worsening of Tourette's Syndrome: CNS stimulants, including dextroamphetamine sulfate, have been associated with the onset or exacerbation of motor and verbal tics and worsening of Tourette's syndrome. Assess the family history and clinically evaluate patients for tics or Tourette’s syndrome before initiating dextroamphetamine sulfate. Regularly monitor patients for the emergence or worsening of tics or Tourette’s syndrome and discontinue treatment if clinically appropriate.

ADVERSE REACTIONS

  • Cardiovascular: Palpitations, tachycardia, elevation of blood pressure. There have been isolated reports of cardiomyopathy associated with chronic amphetamine use.
  • Central Nervous System: Psychotic episodes at recommended doses (rare), overstimulation, restlessness, dizziness, insomnia, euphoria, dyskinesia, dysphoria, tremor, headache, exacerbation of motor and verbal tics and Tourette’s syndrome.
  • Gastrointestinal: Dryness of the mouth, unpleasant taste, diarrhea, constipation, intestinal ischemia and other gastrointestinal disturbances. Anorexia and weight loss may occur as undesirable effects.
  • Allergic: Urticaria.
  • Endocrine: Impotence, changes in libido.
  • Musculoskeletal: Rhabdomyolysis.

USE IN SPECIFIC POPULATIONS

  • Pregnancy Category C: Animal reproduction studies have shown an adverse effect on the fetus. While there are no adequate and well-controlled studies in pregnant women, there has been one report of severe congenital bony deformity, tracheoesophageal fistula, and anal atresia (VATER association) in a baby born to a woman who took dextroamphetamine sulfate with lovastatin during the first trimester of pregnancy. Dextroamphetamine sulfate should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Infants born to mothers dependent on amphetamines have an increased risk of premature delivery and low birth weight. Also, these infants may experience symptoms of withdrawal as demonstrated by dysphoria, including agitation, and significant lassitude.
  • Nursing Mothers: Amphetamines are excreted in human milk. Mothers taking amphetamines should be advised to refrain from nursing.
  • Pediatric Use: Long-term effects of amphetamines in pediatric patients have not been well established. Amphetamines are not recommended for use in pediatric patients under 3 years of age with ADHD. Clinical experience suggests that in psychotic children, administration of amphetamines may exacerbate symptoms of behavior disturbance and thought disorder. Drug treatment is not indicated in all cases of ADHD and should be considered only in light of the complete history and evaluation of the child.

DRUG ABUSE AND DEPENDENCE

  • Dextroamphetamine sulfate is a Schedule II controlled substance.
  • Abuse – Dextroamphetamine sulfate has a high potential for abuse, misuse, and substance use disorder, including addiction. Dextroamphetamine sulfate can be diverted for non-medical use into illicit channels or distribution. Misuse and abuse of amphetamines may cause increased heart rate, respiratory rate, or blood pressure; sweating; dilated pupils; hyperactivity; restlessness; insomnia; decreased appetite; loss of coordination; tremors; flushed skin; vomiting; abdominal pain; anxiety; psychosis; hostility; aggression; and/or suicidal or homicidal ideation. Misuse and abuse of CNS stimulants, including dextroamphetamine sulfate, can result in overdose and death. This risk is increased with higher doses or unapproved methods of administration, such as snorting or injection.
  • Physical Dependence – Dextroamphetamine sulfate may produce physical dependence, manifested by withdrawal signs and symptoms after abrupt discontinuation or a significant dose reduction, including dysphoric mood; depression; fatigue; vivid, unpleasant dreams; insomnia or hypersomnia; increased appetite; and psychomotor retardation or agitation.
  • Tolerance – Dextroamphetamine sulfate may produce tolerance (i.e., a higher dose of a drug is required to produce the same effect that was once obtained at a lower dose).

OVERDOSE

Clinical Effects of Overdose

Overdose of CNS stimulants is characterized by the following sympathomimetic effects:

  • Cardiovascular effects including tachyarrhythmias, and hypertension or hypotension. Vasospasm, myocardial infarction, or aortic dissection may precipitate sudden cardiac death. Takotsubo cardiomyopathy may develop.
  • CNS effects including psychomotor agitation, confusion, and hallucinations. Serotonin syndrome, seizures, cerebral vascular accidents, and coma may occur.
  • Life-threatening hyperthermia (temperatures greater than 104°F) and rhabdomyolysis may develop.

Overdose Management

Consider the possibility of multiple drug ingestion. D-amphetamine is not dialyzable.
Consider contacting the Poison Help line (1-800-222-1222) or a medical toxicologist for additional overdose management recommendations.

This is not a complete summary of safety information. For additional safety information, see Full Prescribing Information and Medication Guide.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.